Home Cart Sign in  
Chemical Structure| 64-73-3 Chemical Structure| 64-73-3

Structure of Demeclocycline HCl
CAS No.: 64-73-3

Chemical Structure| 64-73-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Demeclocycline HCl is a tetracycline antibiotic used for the treatment of bacterial infections, such as Lyme disease, acne, and bronchitis.

Synonyms: Demeclocycline (hydrochloride); Demethyltetracycline; Demethylchlortetracycline

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Demeclocycline HCl

CAS No. :64-73-3
Formula : C21H22Cl2N2O8
M.W : 501.31
SMILES Code : O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])[C@H](O)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4Cl)N.[H]Cl
Synonyms :
Demeclocycline (hydrochloride); Demethyltetracycline; Demethylchlortetracycline
MDL No. :MFCD00082371
InChI Key :OAPVUSSHCBRCOL-KBHRXELFSA-N
Pubchem ID :54686764

Safety of Demeclocycline HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H351-H361
Precautionary Statements:P261-P280

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse midbrain dopamine (DA) neurons 0.5–10 µM DMC provided significant protection to DA neurons against iron-mediated neurodegeneration at concentrations as low as 1 µM, with an EC50 estimated at 1.84 µM. PMC10045597
Human monocytes 10 µM 48 h To evaluate the indirect effects of demeclocycline-activated monocytes on BTIC growth, results showed that conditioned medium from demeclocycline-activated monocytes significantly reduced BTIC growth. PMC7047330
Human brain tumor-initiating cells (BTICs) 1, 5, 10 µM 72 h To evaluate the direct effects of demeclocycline on BTIC growth, results showed that demeclocycline significantly reduced sphere formation and cell number of BTICs. PMC7047330
Pseudomonas aeruginosa PAO1 30 μM 24 h Evaluate the inhibitory effect of DMCT on PAO1 planktonic cells or biofilms, with an inhibition rate >50%. PMC7755642

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Adult Swiss mice Adult Swiss mice Subcutaneous injection 40 mg/kg Single injection, sacrificed at 30 min, 1 h, 8 h, and 24 h post-treatment Evaluated brain permeability of DMC, with a brain-to-plasma ratio of 0.21 ± 0.05, indicating better brain penetration compared to DOX. PMC10045597
CD-1 mice Cutaneous abscess model Subcutaneous injection 5 mg/kg Single dose, lasting 3 days Evaluate the synergistic effect of DMCT combined with SAAP-148 in the PAO1 cutaneous abscess model, showing significant reduction in bacterial load and abscess area. PMC7755642

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<
NCT02771535 Unipolar Depression Not Applicable Completed - Germany ... More >> University Medical Center Hamburg Eppendorf Hamburg, Germany, 20246 Less <<
NCT03268434 Unipolar Depression Not Applicable Recruiting September 2019 Germany ... More >> Asklepios Klinik Nord-Ochsenzoll Recruiting Hamburg, Germany, 22419 Contact: Marion Hagemann-Goebel, Dr. Less <<
NCT01753856 Osteoporosis Phase 4 Completed - United States, Colorado ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lakewood, Colorado, United States, 80227 United States, Georgia For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gainesville, Georgia, United States, 30501 United States, Michigan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Detroit, Michigan, United States, 48202 United States, Nebraska For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Omaha, Nebraska, United States, 68131 Canada, British Columbia For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vancouver, British Columbia, Canada, V5Z 4E1 Canada, Quebec For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sainte-Foy, Quebec, Canada, G1V 3M7 Less <<
NCT01279187 - Terminated(Study was terminate... More >>d due to patient complications unrelated to study drugs) Less << - -
NCT01279187 Implant Phase 2 Terminated(Study was terminate... More >>d due to patient complications unrelated to study drugs) Less << - United States, Michigan ... More >> Michigan Center for Oral Health Research Ann Arbor, Michigan, United States, 48106 Less <<
NCT00873808 - Withdrawn(lack of accrual) - United States, Washington ... More >> University Cancer Center at University of Washington Medical Center Seattle, Washington, United States, 98195-6043 Less <<
NCT01753856 - Completed - -
NCT02576652 Osteoporosis Phase 4 Completed - United States, New York ... More >> Helen Hayes Hospital West Haverstraw, New York, United States, 10993 Research Site West Haverstraw, New York, United States, 10993 Less <<
NCT02740933 Brain Tumor Phase 1 Not yet recruiting January 2021 United States, Massachusetts ... More >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: William T Curry, MD    617-726-3779       Principal Investigator: William T Curry, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.97mL

1.99mL

1.00mL

19.95mL

3.99mL

1.99mL

References

 

Historical Records

Categories